Medtech is entering 2026 with a healthier M&A environment supported by improved financing conditions, resilient sector performance, and a more straightforward path for strategic buyers and private equity.
PMCF Investment Banking Managing Director Bryan Hughes and Vice President Mike Brooks recently discussed 2026 MedTech M&A trends with Medical Design Briefs, explaining how high-quality assets continue to command premium pricing.
“Ample capital is waiting on the sidelines,” Brooks and Hughes said, pointing to record private equity dry powder and more favorable lending conditions entering the new year.
Against this backdrop, MedTech engineering teams are increasingly central to valuation discussions, as the focus shifts to scalable, innovative products.
Hughes and Brooks reviewed several MedTech subsectors, including disposables, contract manufacturing, and digital health, noting that “Investors will pay premiums for innovation coupled with resilience.”
Discussing further 2025 M&A MedTech market trends with Medical Device and Diagnostic Industry (MD+DI), Hughes cited tariff uncertainty as one key factor, while adding, “The industry is quite resilient, and many industry participants have successfully mitigated tariff exposure.”
Hughes also told MD+DI that, looking ahead to 2026, interest and opportunities remain in the MedTech sector.
“Policy changes in Washington had a meaningful impact on M&A activity during much of 2025, including tariff policy, reorganization of CMS and associated cuts in Medicare/Medicaid programs, and broader, more fundamental changes in economic policy created a complex backdrop for deal evaluation,” Hughes said. “But with any change, there is also significant opportunity and with companies now having a better sense of the playing field, and we expect activity to pick up in 2026.”
To read the Medical Design Briefs article, click here
To read the MD+DI article, click here
To learn more about PMCF Investment Banking’s Healthcare and MedTech expertise, click here
